A recent analysis of the federal government’s 340B drug discount program suggests that program eligibility is too broad and that lawmakers need to tighten it, which may mean that hundreds of hospitals ...

Despite the rancor, there are many bipartisan opportunities for the divided 118 th Congress. Near the top of the to-do list should be reforming the well-intentioned, but poorly designed, 340B drug ...

The AHA and several safety-net providers argue that an upcoming mandatory rebate pilot violates administrative law, imposes millions in costs, and threatens patient care in vulnerable communities.

Recent data released by the Health Resources and Services Administration show that drug purchases made under the 340B Drug Pricing Program totaled $81.4 billion in 2024.

The 340B Program has continued to undergo significant upheaval in 2024 that has the potential to bring about impactful changes to how the 340B Program operates moving forward. These developments have ...

The 340B Drug Pricing Program was developed more than three decades ago to help improve access to medicines for vulnerable patients 4 via manufacturer discounts to specific nonprofit hospitals and ...

The results indicate that the program could play a role in discouraging use of biosimilars in the United States. Hospitals participating in the 340B Drug Pricing Program had lower biosimilar uptake, ...

Two recent federal court cases signal new significant developments with respect to the 340B Drug Pricing Program. Specifically: (1) new federal district court litigation challenging a recent HRSA ...

On May 28, representatives from three states introduced a federal bill to amend the 340B program by recognizing contract pharmacies, restricting pharmacy benefit managers and tightening eligibility ...

Hospitals are up in arms over new guidance issued by the Health Resources and Services Administration on Thursday that could restrict the eligibility of their outpatient clinics for drug discounts in ...

New research has found the 340B program is slowing uptake of biosimilars by incentivizing use of more expensive biologics. The 340B program has driven provider variation in the uptake of biosimilars ...

Too often Kansans hear the rotors of another air ambulance carrying a patient from a rural area to an urban health care facility to receive treatment. Like a beating drum, the sound reminds us of the ...